RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2018 Spotlight

RealTime Dynamix™: Bone and Mineral Metabolism US Q1 2018 Spotlight

hyperkalemia q1

This quarterly report series focuses on tracking key performance metrics for phosphate binders, calcimimetics and vitamin D agents in both the dialysis and CKD-ND settings. Emphasis is placed on recently launched products (Rayaldee and Parsabiv) and pipeline agents such as Ardelyx’s tenapanor. See complimentary highlights from the Q1 2018 wave of RealTime Dynamix™: Bone and Mineral Metabolism US below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

2018-05-24T18:03:42+00:00